Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Mitral Regurgitation Using a Minimally Invasive Approach With the HARPOON Device.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is \> 18 years old~2. Presence of severe MR as read on a transthoracic echocardiographic study~3. Mitral leaflet coaptation surface is sufficient to reduce mitral regurgitation without undue leaflet tension (approximate leaflet to gap ratio of 2:1) based on the judgment of the patient eligibility committee and the operating surgeon~4. Degenerative mitral valve disease with mid-segment P2 prolapse~5. Patient is able to sign informed consent and able to return for follow-up and is capable of participating in all testing associated with this clinical investigation~Exclusion Criteria:~1. Patient is of the age where further growth is expected~2. Active endocarditis~3. Left ventricular or left atrial appendage thrombus~4. Severe mitral annular and/or leaflet calcification~5. Cannot tolerate procedural anticoagulation or post-procedure antiplatelet regimen~6. Mitral stenosis~7. Functional Mitral Valve disease~8. Previous mitral valve replacement surgery~9. Fragile or thinning apex~10. Contraindications to transoesophageal echocardiography (atlantoaxial disease, severe generalized cervical arthritis, upper gastrointestinal bleeding, significant dysphagia and odynophagia, has received extensive radiation to the mediastinum)~11. Patient is pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HARPOON MVRS (Type: OTHER): Subjects who were treated with the HARPOON MVRS.

Based on this trial design, predict the completion outcome and termination type (if applicable).